



KHIRON



Zerenia

GREEN KNIGHT
EXCLUSIVE VARIETY



DRIED CANNABIS FLOWERS



FIRST JERSEY GROWN



PACK SIZE



FOR VAPORISING




GENERAL PRODUCT INFORMATION

PRODUCT NAME:	KHIRON GK 24/1	SUB-TYPE:	Hybrid*
VARIETY:	GREEN KNIGHT	MAIN TERPENES:	Caryophyllene Limonene Myrcene
LINEAGE:	ORIGINAL GLUE X OG KUSH X JACK HERER	PLACE OF MANUFACTURE:	Jersey
THC:	24%	CULTIVATION:	Greenhouse
CBD:	≤1%	IRRADIATION:	Non-Irradiated
CANNABINOID PROFILE:	Chemotype I (THC-predominant)		

*According to the current state of research, no clear active ingredient profiles can be assigned to the subspecies of the cannabis plant (i.e. sativa versus indica). The effect of the different varieties depends mainly on the chemotype, which is determined by the relative amounts of THC and CBD!

MEDICAL USES



CHRONIC [2-7]



MULTIPLE SCLEROSIS [2,3,10]



CINV & ANOREXIA [2,3,8,9]



SLEEP DISORDERS [2,3,11,12]



TOURETTE'S SYNDROME [13,14]



PTSD [15,16]

For more information about the therapeutic application possibilities, please visit www.khironmed.co.uk.

REFERENCES

1. Piomelli D, Russo EB. The Cannabis sativa Versus Cannabis indica Debate: An Interview with Ethan Russo, MD. Cannabis Cannabinoid Res. 2016 Jan 1;1(1):44-46. 2. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research | The National Academies Press (2017). 3. Health Canada. Information for Health Care Professionals: Cannabis (marijuana, marijuana) and the cannabinoids. 2013. 4. Andrae, M. H. et al. Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data. J. Pain 16, 1221-1232 (2015). 5. Mücke, M., Phillips, T., Radbruch, L., Petzke, F. & Häuser, W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews vol. 2018 (2018). 6. Van De Donk, T. et al. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with bromyalgia. Pain 160, 860-869 (2019). 7. Romero-Sandoval, E. A., Kolano, A. L. & Alvarado-Vázquez, P. A. Cannabis and Cannabinoids for Chronic Pain. Current Rheumatology Reports vol. 19 (2017). 8. Machado Rocha, F. C., Stéfano, S. C., De Cássia Haiek, R., Rosa Oliveira, L. M. O. & Da Silveira, D. X. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: Systematic review and meta-analysis. European Journal of Cancer Care vol. 17 431-443 (2008). 9. Cyr, C. et al. Cannabis in palliative care: Current challenges and practical recommendations. Annals of Palliative Medicine vol. 7 463-477 (2018). 10. Rice, J. & Cameron, M. Cannabinoids for Treatment of MS Symptoms: State of the Evidence. Current Neurology and Neuroscience Reports vol. 18 (2017). 11. Choi, S., Huang, B. C. & Gamaldo, C. E. Therapeutic Uses of Cannabis on Sleep Disorders and Related Conditions. Journal of Clinical Neurophysiology vol. 37 39-49 (2020). 12. Mondino, A. et al. Acute effect of vaporized Cannabis on sleep and electrocortical activity. Pharmacol. Biochem. Behav. 179, 113-123 (2019). 13. Müller-Vahl, K. R. Treatment of Tourette syndrome with cannabinoids. Behav. Neurol. 27, 119-24 (2013). 14. Milosev, L. M., Psathakis, N., Szejko, N., Jakubovski, E. & Müller-Vahl, K. R. Treatment of Gilles de la Tourette Syndrome with Cannabis-Based Medicine: Results from a Retrospective Analysis and Online Survey. Cannabis cannabinoid Res. 4, 265-274 (2019). 15. Orsolini, L. et al. Use of medicinal cannabis and synthetic cannabinoids in post-traumatic stress disorder (PTSD): A systematic review. Medicina (Lithuania) vol. 55 (2019). 16. Bonn-Miller, M. O., Babson, K. A. & Vandrey, R. Using cannabis to help you sleep: Heightened frequency of medical cannabis use among those with PTSD. Drug Alcohol Depend. 136, 162-165 (2014).